SIX1 is overexpressed in multiple cancer types, including breast cancer and liver cancer, and its high expression predicts poor clinical outcomes.13–16 Therefore, disrupting the ERK/SIX1 interaction may open up a new way for cancer treatment. This evidence concerns the gene MAPK1 and breast carcinoma.